Showing results (1811-1820 of 9,628) with videos related to
Sort By:
Pageof 963
Leukemia|June 8, 2007
MALT lymphoma in patients with autoimmune diseases: a comparative analysis of characteristics and clinical courseS Wöhrer, M Troch, B Streubel, et al.Leukemia|June 8, 2007
The emerging role of Wnt signaling in the pathogenesis of acute myeloid leukemiaJ-H Mikesch, B Steffen, W E Berdel, et al.Leukemia|May 15, 2007
Genome-wide detection of recurring sites of uniparental disomy in follicular and transformed follicular lymphomaJ Fitzgibbon, S Iqbal, A Davies, et al.Leukemia|July 6, 2007
Acute bilineal leukemia: a rare disease with poor outcomeE G Weir, M Ali Ansari-Lari, D A S Batista, et al.Leukemia|July 6, 2007
The effect of novel anti-myeloma agents on bone metabolism of patients with multiple myelomaE Terpos, M-A Dimopoulos, O SezerLeukemia|July 6, 2007
UGT1A1 promoter polymorphism increases risk of nilotinib-induced hyperbilirubinemiaJ B Singer, Y Shou, F Giles, et al.Leukemia|July 20, 2007
The histone deacetylase inhibitor ITF2357 has anti-leukemic activity in vitro and in vivo and inhibits IL-6 and VEGF production by stromal cellsJ Golay, L Cuppini, F Leoni, et al.Leukemia|July 20, 2007
Clinical evaluation of BCR-ABL peptide immunisation in chronic myeloid leukaemia: results of the EPIC studyJ M Rojas, K Knight, L Wang, et al.Leukemia|February 13, 2009
GATA-1 and GATA-2 binding to 3' enhancer of WT1 gene is essential for its transcription in acute leukemia and solid tumor cell linesA Furuhata, M Murakami, H Ito, et al.Leukemia|February 13, 2009
FIP1L1-PDGFRalpha D842V, a novel panresistant mutant, emerging after treatment of FIP1L1-PDGFRalpha T674I eosinophilic leukemia with single agent sorafenibE Lierman, L Michaux, E Beullens, et al.Pageof 963